about
Imaging of liver cancer.Multiwalled carbon nanotube hybrids as MRI contrast agentsContrast Enhanced MRI in the Diagnosis of HCCDesign of ProCAs (protein-based Gd(3+) MRI contrast agents) with high dose efficiency and capability for molecular imaging of cancer biomarkersRational design for multifunctional non-liposomal lipid-based nanocarriers for cancer management: theory to practice.Manganese doped fluorescent paramagnetic nanocrystals for dual-modal imaging.Targeted gadolinium-loaded dendrimer nanoparticles for tumor-specific magnetic resonance contrast enhancement.Responsive MRI agents for sensing metabolism in vivo.Nuclear microscopy: a novel technique for quantitative imaging of gadolinium distribution within tissue sections.Gadolinium-conjugated dendrimer nanoclusters as a tumor-targeted T1 magnetic resonance imaging contrast agentGd(III) functionalized gold nanorods for multimodal imaging applications.Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics.Optimization of gadolinium-based MRI contrast agents for high magnetic-field applications.Development of EGFR-targeted nanoemulsion for imaging and novel platinum therapy of ovarian cancerElemental imaging of MRI contrast agents: benchmarking of LA-ICP-MS to MRI.Effect of MR contrast agents on quantitative accuracy of PET in combined whole-body PET/MR imaging.Safety and Efficacy of Gadobutrol for Contrast-enhanced Magnetic Resonance Imaging of the Central Nervous System: Results from a Multicenter, Double-blind, Randomized, Comparator Study.A transferrin-target magnetic/fluorescent dual-mode probe significantly enhances the diagnosis of non-small cell lung cancer.Heterogeneous dimer peptide-conjugated polylysine dendrimer-Fe3O4 composite as a novel nanoscale molecular probe for early diagnosis and therapy in hepatocellular carcinomaApplication of atomic force microscopy in morphological observation of antisense probe labeled with magnetismStrategies for Target-Specific Contrast Agents for Magnetic Resonance Imaging(89)Zr-labeled paramagnetic octreotide-liposomes for PET-MR imaging of cancerA choline derivate-modified nanoprobe for glioma diagnosis using MRI.Introductory Chemistry: A Molar Relaxivity Experiment in the High School Classroom.Immediate Adverse Reactions to Gadolinium-Based MR Contrast Media: A Retrospective Analysis on 10,608 ExaminationsCombining hyperpolarized 13 C MRI with a liver-specific gadolinium contrast agent for selective assessment of hepatocyte metabolism.Improved quantification of myocardial blood flow using highly constrained back projection reconstruction.Paramagnetic liposome nanoparticles for cellular and tumour imaging.Clinical applications of gadobenate dimeglumine-enhanced magnetic resonance cholangiography: an expanded pictorial review.Biological applications of magnetic nanoparticles.Engineering Gd-loaded nanoparticles to enhance MRI sensitivity via T(1) shortening.Advanced Functional Nanomaterials for Theranostics.Clinically Approved Nanoparticle Imaging Agents.Different cell responses induced by exposure to maghemite nanoparticles.RGD-modified poly(D,L-lactic acid) nanoparticles enhance tumor targeting of oridonin.Imaging Glycosylation In Vivo by Metabolic Labeling and Magnetic Resonance Imaging.Gadolinium in pediatric cardiovascular magnetic resonance: what we know and how we practice.Gadolinium compounds signaling through TLR4 and TLR7 in normal human macrophages: establishment of a proinflammatory phenotype and implications for the pathogenesis of nephrogenic systemic fibrosis.Augmenting regional and targeted delivery in the pulmonary acinus using magnetic particlesImaging Glycosylation In Vivo by Metabolic Labeling and Magnetic Resonance Imaging.
P2860
Q24654739-5E8305E7-E1AB-4AAE-BB47-E97BBDFC8BDBQ26740054-ED98A0D2-D671-43C9-B849-614CC01E3F58Q26768472-D62E398D-E431-4258-9BF5-EFF9803E7DD4Q28235682-ABA2C1B0-AD09-427A-BB4C-5A13B0A7AAB2Q30436623-4856422A-1B0E-4B97-979A-F23627A9A435Q30841850-12EFFE41-3B9B-4FCD-B1A4-E267A354C80BQ31169933-7B3E3E13-8D28-4188-9217-0C0FBD13DFF5Q33415333-995B72B3-BE1D-48B9-B5AC-CDB4ED10ACF9Q33574781-85B2C8BB-B816-4CAA-B988-7CD1299C8301Q33822955-086A30F0-3A9C-43E0-8B7A-D9224C1C0821Q33839558-5B68D136-71B2-4C56-81BA-CC492AC972D1Q33847006-BF8CF827-636B-46A5-9F17-3386FA513B22Q33852473-9919A30C-1D41-4905-B43E-56075CD7D227Q34214594-AACE2CAE-7414-438C-A907-92B963E3CC4EQ34242694-13E4D686-B4A2-426E-BE79-64D7AB015A2FQ34379033-302D7A4F-19D2-4F72-9D55-D9F7C6B72384Q35390321-F795097C-F0C9-482B-8D99-6FA5E6D10688Q36028884-5BE92747-71DD-4708-9DF7-439986CA7B7EQ36292525-76525CC3-13E5-4ACC-BB9A-C7AC36130512Q36478976-26DC1CCC-269F-449C-A633-C1244862ECD4Q36517070-DF0AD850-1EA1-44E1-BC4C-798D064DD938Q36625800-C5D8C2D6-04A9-4C02-82B3-09F72C4C6C42Q36747329-AB9EDE3D-D50F-4B14-A5BC-65F6B1D48588Q37069946-A6833F99-BB34-421B-ABDC-769EC66691F8Q37250096-B3C30456-E87F-402D-91F6-1565DBE7A7FBQ37503563-6BE67B9B-58EF-4AF5-9305-984EAE428F14Q37678720-23FFC835-34E0-43AA-ACA1-D11613D9862FQ37755998-63CB3CFD-DE0E-4D09-9D1D-F86D23C50EBCQ37832178-D04E5645-CA0D-4A1F-B593-2FA13EC489A1Q38000520-0A1FB121-9031-4BE2-BE4D-E9C086307A77Q38155457-993014CF-EAB0-4E1B-8777-7774E8C0FEE3Q38639877-35399E47-0978-4CA8-8840-017F53D77822Q38979886-C20E23D5-2875-4EAB-8C14-5540D7D951C9Q39107521-866D8696-49CE-4388-9726-7AA7C25836FCQ40575295-97995643-75C5-4BD4-A54F-B21C22D108CBQ40744914-E4302629-A209-4C3A-9F1A-1001637327F3Q41391342-21272BD1-D276-4AF8-8444-37E2E449D68FQ41879002-9BF3B4DC-8D57-4998-B80A-33C12EC27D09Q42026547-F91D9752-79D6-4529-80CB-39CA2514962FQ42181384-3B931C0B-ACBD-41A7-AF77-89B18D74AEEC
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
MR contrast agents, the old and the new.
@ast
MR contrast agents, the old and the new.
@en
type
label
MR contrast agents, the old and the new.
@ast
MR contrast agents, the old and the new.
@en
prefLabel
MR contrast agents, the old and the new.
@ast
MR contrast agents, the old and the new.
@en
P1476
MR contrast agents, the old and the new.
@en
P2093
Marie-France Bellin
P304
P356
10.1016/J.EJRAD.2006.06.021
P577
2006-09-26T00:00:00Z